Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations

N. Pankratz, D. K. Kissell, M. W. Pauciulo, C. A. Halter, A. Rudolph, Ronald Pfeiffer, K. S. Marder, T. Foroud, W. C. Nichols

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

OBJECTIVE: Mutations in both alleles of parkin have been shown to result in Parkinson disease (PD). However, it is unclear whether haploinsufficiency (presence of a mutation in only 1 of the 2 parkin alleles) increases the risk for PD. METHODS: We performed comprehensive dosage and sequence analysis of all 12 exons of parkin in a sample of 520 independent patients with familial PD and 263 controls. We evaluated whether presence of a single parkin mutation, either a sequence (point mutation or small insertion/deletion) or dosage (whole exon deletion or duplication) mutation, was found at increased frequency in cases as compared with controls. We then compared the clinical characteristics of cases with 0, 1, or 2 parkin mutations. RESULTS: We identified 55 independent patients with PD with at least 1 parkin mutation and 9 controls with a single sequence mutation. Cases and controls had a similar frequency of single sequence mutations (3.1% vs 3.4%, p = 0.83); however, the cases had a significantly higher rate of dosage mutations (2.6% vs 0%, p = 0.009). Cases with a single dosage mutation were more likely to have an earlier age at onset (50% with onset at ≤45 years) compared with those with no parkin mutations (10%, p = 0.00002); this was not true for cases with only a single sequence mutation (25% with onset at ≤45 years, p = 0.06). CONCLUSIONS: Parkin haploinsufficiency, specifically for a dosage mutation rather than a point mutation or small insertion/deletion, is a risk factor for familial PD and may be associated with earlier age at onset.

Original languageEnglish (US)
Pages (from-to)279-286
Number of pages8
JournalNeurology
Volume73
Issue number4
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Parkinson Disease
Virulence
Mutation
Haploinsufficiency
Age of Onset
Point Mutation
Exons
Alleles
Mutation Rate
Sequence Analysis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pankratz, N., Kissell, D. K., Pauciulo, M. W., Halter, C. A., Rudolph, A., Pfeiffer, R., ... Nichols, W. C. (2009). Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology, 73(4), 279-286. https://doi.org/10.1212/WNL.0b013e3181af7a33

Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. / Pankratz, N.; Kissell, D. K.; Pauciulo, M. W.; Halter, C. A.; Rudolph, A.; Pfeiffer, Ronald; Marder, K. S.; Foroud, T.; Nichols, W. C.

In: Neurology, Vol. 73, No. 4, 07.2009, p. 279-286.

Research output: Contribution to journalArticle

Pankratz, N, Kissell, DK, Pauciulo, MW, Halter, CA, Rudolph, A, Pfeiffer, R, Marder, KS, Foroud, T & Nichols, WC 2009, 'Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations', Neurology, vol. 73, no. 4, pp. 279-286. https://doi.org/10.1212/WNL.0b013e3181af7a33
Pankratz, N. ; Kissell, D. K. ; Pauciulo, M. W. ; Halter, C. A. ; Rudolph, A. ; Pfeiffer, Ronald ; Marder, K. S. ; Foroud, T. ; Nichols, W. C. / Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. In: Neurology. 2009 ; Vol. 73, No. 4. pp. 279-286.
@article{1792d38d4de546e9a4e4422657a4e1fa,
title = "Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations",
abstract = "OBJECTIVE: Mutations in both alleles of parkin have been shown to result in Parkinson disease (PD). However, it is unclear whether haploinsufficiency (presence of a mutation in only 1 of the 2 parkin alleles) increases the risk for PD. METHODS: We performed comprehensive dosage and sequence analysis of all 12 exons of parkin in a sample of 520 independent patients with familial PD and 263 controls. We evaluated whether presence of a single parkin mutation, either a sequence (point mutation or small insertion/deletion) or dosage (whole exon deletion or duplication) mutation, was found at increased frequency in cases as compared with controls. We then compared the clinical characteristics of cases with 0, 1, or 2 parkin mutations. RESULTS: We identified 55 independent patients with PD with at least 1 parkin mutation and 9 controls with a single sequence mutation. Cases and controls had a similar frequency of single sequence mutations (3.1{\%} vs 3.4{\%}, p = 0.83); however, the cases had a significantly higher rate of dosage mutations (2.6{\%} vs 0{\%}, p = 0.009). Cases with a single dosage mutation were more likely to have an earlier age at onset (50{\%} with onset at ≤45 years) compared with those with no parkin mutations (10{\%}, p = 0.00002); this was not true for cases with only a single sequence mutation (25{\%} with onset at ≤45 years, p = 0.06). CONCLUSIONS: Parkin haploinsufficiency, specifically for a dosage mutation rather than a point mutation or small insertion/deletion, is a risk factor for familial PD and may be associated with earlier age at onset.",
author = "N. Pankratz and Kissell, {D. K.} and Pauciulo, {M. W.} and Halter, {C. A.} and A. Rudolph and Ronald Pfeiffer and Marder, {K. S.} and T. Foroud and Nichols, {W. C.}",
year = "2009",
month = "7",
doi = "10.1212/WNL.0b013e3181af7a33",
language = "English (US)",
volume = "73",
pages = "279--286",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations

AU - Pankratz, N.

AU - Kissell, D. K.

AU - Pauciulo, M. W.

AU - Halter, C. A.

AU - Rudolph, A.

AU - Pfeiffer, Ronald

AU - Marder, K. S.

AU - Foroud, T.

AU - Nichols, W. C.

PY - 2009/7

Y1 - 2009/7

N2 - OBJECTIVE: Mutations in both alleles of parkin have been shown to result in Parkinson disease (PD). However, it is unclear whether haploinsufficiency (presence of a mutation in only 1 of the 2 parkin alleles) increases the risk for PD. METHODS: We performed comprehensive dosage and sequence analysis of all 12 exons of parkin in a sample of 520 independent patients with familial PD and 263 controls. We evaluated whether presence of a single parkin mutation, either a sequence (point mutation or small insertion/deletion) or dosage (whole exon deletion or duplication) mutation, was found at increased frequency in cases as compared with controls. We then compared the clinical characteristics of cases with 0, 1, or 2 parkin mutations. RESULTS: We identified 55 independent patients with PD with at least 1 parkin mutation and 9 controls with a single sequence mutation. Cases and controls had a similar frequency of single sequence mutations (3.1% vs 3.4%, p = 0.83); however, the cases had a significantly higher rate of dosage mutations (2.6% vs 0%, p = 0.009). Cases with a single dosage mutation were more likely to have an earlier age at onset (50% with onset at ≤45 years) compared with those with no parkin mutations (10%, p = 0.00002); this was not true for cases with only a single sequence mutation (25% with onset at ≤45 years, p = 0.06). CONCLUSIONS: Parkin haploinsufficiency, specifically for a dosage mutation rather than a point mutation or small insertion/deletion, is a risk factor for familial PD and may be associated with earlier age at onset.

AB - OBJECTIVE: Mutations in both alleles of parkin have been shown to result in Parkinson disease (PD). However, it is unclear whether haploinsufficiency (presence of a mutation in only 1 of the 2 parkin alleles) increases the risk for PD. METHODS: We performed comprehensive dosage and sequence analysis of all 12 exons of parkin in a sample of 520 independent patients with familial PD and 263 controls. We evaluated whether presence of a single parkin mutation, either a sequence (point mutation or small insertion/deletion) or dosage (whole exon deletion or duplication) mutation, was found at increased frequency in cases as compared with controls. We then compared the clinical characteristics of cases with 0, 1, or 2 parkin mutations. RESULTS: We identified 55 independent patients with PD with at least 1 parkin mutation and 9 controls with a single sequence mutation. Cases and controls had a similar frequency of single sequence mutations (3.1% vs 3.4%, p = 0.83); however, the cases had a significantly higher rate of dosage mutations (2.6% vs 0%, p = 0.009). Cases with a single dosage mutation were more likely to have an earlier age at onset (50% with onset at ≤45 years) compared with those with no parkin mutations (10%, p = 0.00002); this was not true for cases with only a single sequence mutation (25% with onset at ≤45 years, p = 0.06). CONCLUSIONS: Parkin haploinsufficiency, specifically for a dosage mutation rather than a point mutation or small insertion/deletion, is a risk factor for familial PD and may be associated with earlier age at onset.

UR - http://www.scopus.com/inward/record.url?scp=68249129262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249129262&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e3181af7a33

DO - 10.1212/WNL.0b013e3181af7a33

M3 - Article

C2 - 19636047

AN - SCOPUS:68249129262

VL - 73

SP - 279

EP - 286

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -